The GenomeWeb Index fell 2 percent, outperforming the Nasdaq Biotechnology Index but doing worse than the Dow Jones and the Nasdaq.
The company's Lyo-Ready 1-Step RT-qPCR mix is being used by diagnostic labs in China to develop screening assays for the virus.
The index's gain was well above the 13 percent increase of 2018, and almost reached the 39 percent increase it saw in 2017.
The GenomeWeb Index vastly outperformed the Dow Jones and the Nasdaq Biotechnology Index this month, while slightly underperforming the Nasdaq.
BD said TRC Capital Investment had made an unsolicited offer to BD shareholders to buy up to 500,000 shares of BD's stock at a price below the current market value.
The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.
The GenomeWeb index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index.
The UK Competition and Markets Authority said blocking the deal could prevent a "substantial lessening of competition" in the NGS market.
Shares of firm fell 47 percent on the news it will sell 20.9 million common shares along with warrants to purchase up to the same number of shares.
Though Meehan was cautious on Waters in the near term, he provided a favorable outlook on Thermo Fisher Scientific.
The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.
The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.